ACIC 200 MG tablett Eesti - eesti - Ravimiamet

acic 200 mg tablett

lex ano uab - atsikloviir - tablett - 200mg 25tk

ACIC 400 MG tablett Eesti - eesti - Ravimiamet

acic 400 mg tablett

lex ano uab - atsikloviir - tablett - 400mg 70tk; 400mg 35tk

ACIC 400 MG tablett Eesti - eesti - Ravimiamet

acic 400 mg tablett

ideal trade links uab - atsikloviir - tablett - 400mg 35tk

ACICLOVIR ACTAVIS kreem Eesti - eesti - Ravimiamet

aciclovir actavis kreem

teva b.v. - atsikloviir - kreem - 50mg 1g 5g 1tk; 50mg 1g 10g 1tk

ACIC 5% kreem Eesti - eesti - Ravimiamet

acic 5% kreem

sandoz pharmaceuticals d.d. - atsikloviir - kreem - 50mg 1g 2g 1tk

ACICLOVIR ACTAVIS tablett Eesti - eesti - Ravimiamet

aciclovir actavis tablett

actavis nordic a/s - atsikloviir - tablett - 400mg 10tk

ACIC 400 MG tablett Eesti - eesti - Ravimiamet

acic 400 mg tablett

globalex pharma oÜ - atsikloviir - tablett - 400mg 35tk; 400mg 70tk

ACIC-OPHTAL silmasalv Eesti - eesti - Ravimiamet

acic-ophtal silmasalv

dr. winzer pharma gmbh - atsikloviir - silmasalv - 30mg 1g 4.5g 1tk

ACICLOVIR-RATIOPHARM infusioonilahuse pulber Eesti - eesti - Ravimiamet

aciclovir-ratiopharm infusioonilahuse pulber

merckle gmbh - atsikloviir - infusioonilahuse pulber - 250mg 5tk

Verzenios Euroopa Liit - eesti - EMA (European Medicines Agency)

verzenios

eli lilly nederland b.v. - abemaciclib - rinnanäärmed - antineoplastilised ained - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.